Drug Approval | June 27, 2025
Biocon Biologics receives Health Canada approval for Yesafili
The approval is based on a comprehensive package of analytical, nonclinical, and clinical data
The approval is based on a comprehensive package of analytical, nonclinical, and clinical data
Changhua site meets international regulatory standards for global medical applications
The 16,000-square-foot expansion enhances DuPont’s global sterile operations
The approval is for the generic version of Victoza, indicated for the treatment of insufficiently controlled Type 2 Diabetes Mellitus
Certification bolsters Venus Remedies' position in PIC/S markets, reinforcing commitment to global quality standards
For the full financial year FY25, revenue from operations grew 9 per cent to Rs. 11,537.8 crore, compared to Rs. 10,588 crore in FY24.
Durable pain relief from a single MM-II injection and its cartilage-protective effects in OA modelsfeatured in two peer-reviewed articles
Phytonadione Injectable Emulsion possesses the same type and degree of activity as does naturally-occurring vitamin K
PRX-PLUS has a unique product feature with its deep-impacting formula
Subcutaneous pembrolizumab administered every six weeks with a median injection time of two minutes, in combination with chemotherapy, shows consistent results across reported efficacy and safety endpoints compared to IV KEYTRUDA in combination with chemotherapy
Subscribe To Our Newsletter & Stay Updated
